COVID Vaccines, what’s new: an update on the latest clinical trials that are underway with the currently administered vaccines
The global pandemic posed a challenge for the launch of safe and effective vaccines with a lighting speed. Pharma companies have quickly developed the vaccines and regulatory agencies have assessed with emergency approvals. In the second year of this pandemic, as the vaccination process is ongoing and with the ‘relaxing’ of rules in certain states, in this blog we tried to shed some light on the next steps and updates associated with the vaccines, especially in the context of clinical trials.
COVID19 vaccines currently administered in the US are based on mRNA and viral vector technologies. Both vaccines contain the genetic material of SARS-CoV-2 spike protein. Once injected, it produces a large number of spike proteins which primes the immune system to fight against the viral infection. The two major mRNA vaccines available in the US are from Pfizer/ BioNtech and Moderna.
• Moderna started testing against the B.1.351 variant and is investigating booster doses on previously vaccinated adults. NCT04785144 NCT04405076 (Ref)
• In one study Pfizer and Moderna vaccines are tested to estimate their systemic allergic reactions. NCT04761822
Comments are closed.